Introduction
The v-myb gene was originally identified as the oncogene of the acutely oncogenic chicken retroviruses avian myeloblastosis virus (AMV) and avian leukemia virus E26. V-myb encodes a transcription factor which is responsible for the ability of these viruses to transform myelomonocytic cells in vivo and in vitro (for review see : Ness, 1996; Lipsick and Wang, 1999; Oh and Reddy, 1999) . V-myb is derived by retroviral transduction from a cellular proto-oncogene, c-myb (Klempnauer et al., 1982 . It has been established that the oncogenicity of v-myb is due to truncations that resulted in the loss of sequences from the 5' and 3' ends of c-myb (Gra¨sser et al., 1991; Dini and Lipsick, 1993) . A large body of evidence has shown that c-myb plays a crucial role in the development of the hematopoietic system. C-myb is highly expressed in immature hematopoietic cells where it is thought to act as a genetic switch that directs hematopoietic progenitor cells to alternative fates, such as proliferation, differentiation and apoptosis (Weston, 1998; Oh and Reddy, 1999) .
The proteins encoded by the viral and cellular myb genes (referred to as v-Myb and c-Myb) bind to the consensus sequence motif PyAAC G /T G (Biedenkapp et al., 1988) and activate promoters containing such binding sites Ness et al., 1989; Nishina et al., 1989; Weston and Bishop, 1989; Ibanez and Lipsick, 1990) . The transforming potential of v-Myb largely correlates with the ability to activate transcription of model reporter genes (Lane et al., 1990; Frampton et al., 1993) , hence it is thought that cell transformation by v-myb is caused by deregulation of specific target genes. The identification of the target genes of v-Myb and c-Myb and the elucidation of their regulation by Myb proteins are therefore essential for understanding the role of Myb proteins in hematopoietic cells. So far, a number of genes expressed in vmyb transformed myeloblasts have been identified as direct targets for v-Myb, including mim-1 (Ness et al., 1989) , the lysozyme gene (Introna et al., 1990) , bcl-2 (Frampton et al., 1996; Taylor et al., 1996) , tom-1 , c-kit (Hogg et al., 1997) , GBX2 (Kowenz-Leutz et al., 1997), Pdcd4 (Schlichter et al., 2001a) and the genes for neutrophil elastase (Oelgeschla¨ger et al., 1996) , the A2B adenosine receptor (A2B-AR) and C/EBPb (Mink et al., 1999) . While the roles of these genes in v-myb dependent cell transformation are not yet fully understood their promoters have been used as tools to study how v-Myb activates gene expression. Insight into these mechanisms has been obtained particularly for those Myb target genes whose expression is restricted to the myelomonocytic lineage, such as mim-1 and tom-1. A recurring theme of this work is the finding that members of the CCAAT-box/enhancer binding protein (C/EBP) transcription factor family act as essential cooperation partners for Myb in myelomonocytic cells (Burk et al., 1993 Ness et al., 1993; Mink et al., 1996) . The cooperation between v-Myb and C/EBP is reflected in the organization of the mim-1 and tom-1 promoters, which both contain crucial Myb and C/ EBP binding sites juxtaposed to each other (Burk et al., 1993 Ness et al., 1993 , Mink et al., 1996 . Cooperation between Myb and C/EBP appears to depend on direct as well as indirect interactions of both proteins (Mink et al., 1996 (Mink et al., , 1997 . In contrast to the effects of Myb on gene expression in myelomonocytic cells, much less is known about how Myb activates target genes in other hematopoietic lineages, where C/ EBP factors are expressed only weakly or not at all. The CD4, RAG2 and TCRg and d genes have been identified as targets of Myb in lymphoid cells (Siu et al., 1992; Hernandez-Munain and Krangel, 1995; Wang et al., 2000; Reizis and Leder, 2001) . In most of these cases a single crucial Myb binding site has been shown to mediate regulation by Myb, presumably in cooperation with other transcription factors.
By using a myelomonocytic cell line expressing an estrogen-inducible version of v-Myb we have previously identified the gene encoding the chicken A2B adenosine receptor (A2B-AR), a member of the seven-pass transmembrane receptor superfamily, as a direct target gene for v-Myb (Worpenberg et al., 1997). The A2B-AR gene has an interesting expression pattern in the hematopoietic system: It is expressed in myelomonocytic as well as in erythroid cells but apparently only weakly (or not at all) in other hematopoietic lineages . The A2B-AR gene therefore offers the opportunity to study how Myb activates a target gene in two different hematopoietic lineages. As a first step towards this goal we here present the identification and the preliminary characterization of the promoter of the chicken A2B-AR gene.
Results

Identification of the promoter of the A2B adenosine receptor gene
To identify the promoter of the chicken A2B-AR gene we screened a library of genomic chicken DNA with a probe derived from a chicken A2B-AR cDNA clone . Hybridization of restriction digests of positive clones with a probe derived from the 5' end of the A2B-AR cDNA suggested that the promoter was located on an approximately 3.4 kb NotI/BglII restriction fragment. This fragment was then subcloned and its complete nucleotide sequence was determined (Figure 1) . Analysis of the sequence identified a stretch of nucleotides that was identical to the 5' end of the A2B-AR cDNA clone . Immediately 3' to this homology is a consensus splice donor site (at position +1017 to +1021 in Figure 1 ) which is followed by sequences not found in the A2B-AR cDNA, indicating the presence of an exon-intron boundary. On the 5' side the sequence around a SmaI restriction site (located at position +216 to +221 in Figure 1 ) was identical to the sequence at the 5' end of the longest A2B-AR cDNA clone available. We therefore concluded that the NotI/BglII fragment contains the first exon of the gene and that the promoter might be located close to the SmaI site. The sequences around the 5' end of the first exon have a GC-content of about 80% and contain similar numbers of CpG and GpC dinucleotides. By contrast, the sequences located upstream or downstream of this region have a GC-content of less than 50% and a CpG to GpC ratio of around 0.2. This indicates that the 5' end of the gene is embedded in a CpG-rich island.
We noted that the region upstream of the SmaI contains a surprisingly large number of potential Myb binding sites. To directly demonstrate that transcription of A2B-AR mRNA is initiated in this region and A to E refer to Myb binding sites which were subjected to mutagenesis. A potential GATA-1 binding site is marked by dotted underlining. A2B-AR coding regions are marked by straight underlining and selected restriction sites are indicated to delineate the transcriptional start site(s) we performed nuclease S1 mapping experiments following the strategy outlined at the top of Figure 2 . An endlabeled probe fragment spanning the putative promoter region was hybridized to mRNA from the v-myb transformed myeloblast cell line BM2 (which expresses high levels of the A2B-AR gene) followed by digestion with nuclease S1. As shown in lane 2 of Figure 2 , several S1-resistant DNA fragments were obtained whereas no such fragments were detected following a control hybridization with tRNA ( Figure 2, lane 1) . This suggested that transcription of the A2B-AR gene starts at multiple sites in the region upstream of the SmaI site. The approximate positions of the transcriptional start sites were determined by comparison to sequencing reactions and are marked in Figure 1 . We noted that the A2B-AR promoter region lacks a canonical TATA-box but instead contains an unusual stretch of thymidine residues immediately preceding the major transcriptional start site.
Multiple Myb binding sites contribute to the Myb-inducibility of the A2B-AR promoter
The presence of multiple Myb binding sites in the A2B-AR promoter region strongly suggested that these sites are responsible for the activation of the promoter by Myb. To demonstrate that v-Myb is able to bind to these sites we performed electrophoretic mobility shift assays using bacterially expressed v-Myb and oligonucleotides corresponding to several of the Myb binding sites. We concentrated on those sites which are located in the vicinity of the major transcriptional start site (these sites are referred to as sites A to E in Figure 1 ). As shown in Figure 3 vMyb formed specific complexes with all sites tested. As expected, mutated variants of these sites failed to bind v-Myb, demonstrating the specificity of binding. We noted that an oligonucleotide containing Myb binding sites B,C and D formed only monomeric complexes with v-Myb, presumably because the spacing of these binding sites is too close.
To further confirm that we have identified the Mybinducible promoter of the A2B-AR gene and to study its regulation in more detail, we constructed a series of luciferase reporter genes, the longest of which contained 1945 base pairs upstream the major transcriptional start site ( Figure 4a ). We then cotransfected this reporter gene with a v-Myb expression vector into QT6 quail fibroblasts. As control, a similar transfection containing empty expression vector was performed. QT6 cells lack endogenous v-Myb or cMyb and are commonly used to monitor the transactivation of Myb-inducible reporter genes. As shown in Figure 4a , the luciferase activity was increased approximately eightfold by v-Myb, demonstrating that this region of the A2B-AR gene indeed acts as a Myb-inducible promoter.
To delineate the sequences that are required for the Myb-inducibility 5' deletion mutants of the A2B-AR promoter were characterized in cotransfection experiments. Figure 4a shows that the sequences upstream of position 7231 bp could be deleted without adversely affecting the inducibility of the promoter by v-Myb, however, further deletion of upstream sequences led to a gradual decrease of the Myb-inducibility. The shortest promoter construct, pi11/5(753)Luc, was virtually unaffected by v-Myb. Since several Myb binding sites reside in the 7231/753 bp region of the promoter these results are consistent with the notion that the Myb binding sites are required for the stimulation of the promoter by v-Myb.
To substantiate that specific DNA-binding by v-Myb is required for the activation of the promoter by v-Myb we cotransfected the reporter gene pGL3-i11/5WT (spanning nucleotides 7231 to +108) with an expression vector for a mutant of v-Myb deleted in the DNA-binding domain. As shown in Figure 4b the promoter was not induced by this mutant of v-Myb, indicating that the stimulation of the A2B-AR promoter by v-Myb is dependent on the specific DNA-binding by v-Myb. Figure 2 Mapping the transcriptional start site of the A2B-AR gene by nuclease S1 digestion. A single-stranded, end-labeled probe fragment spanning sequences from 7522 to +258 bp was hybridized to tRNA (lane 1) or to mRNA prepared from BM2 cells (lane 2). The samples were then treated with S1 nuclease, denatured and analysed by electrophoresis in a sequencing gel. Arrowheads point to S1-resistant DNA-fragments (lower arrow) and residual full-length probe fragment (upper arrow). Lanes A, C, G and T show the products of sequencing reactions To unambiguously demonstrate a role for the Myb binding sites in transcriptional activation by v-Myb we generated point mutations in the pGL3-i11/5WT construct, thereby destroying one or several of the Myb binding sites. Electrophoretic mobility shift assays confirmed that the mutations had indeed abolished the ability of v-Myb to bind to these sites (Figure 3 and data not shown). Figure 5a shows the results of cotransfection studies in which the individual promoter constructs were cotransfected with or without v-Myb expression vector. It is evident that mutation of any of the Myb binding sites A to E resulted in a partial loss of the Myb-inducibility. Furthermore, increasing the number of mutated Myb binding sites further diminished the Myb-inducibility of the promoter. A construct in which the majority of the Myb binding sites were mutated, was virtually unaffected by v-Myb.
In addition to performing cotransfection experiments in QT6 cells we also determined the activity of some of the point-mutated promoter constructs in the v-myb transformed myeloblast cell line BM2 (which expresses v-Myb endogenously) (Figure 5b) . Consistent with the results of the cotransfection experiments the activities of most single point mutations were reduced and the promoter construct in which all Myb binding sites had been destroyed showed the lowest activity.
The A2B-AR promoter is not activated synergistically by Myb and C/EBP Previous analyses of other Myb-regulated genes have implicated the members of the C/EBP family as important cooperation partners for v-Myb in myelomonocytic cells. C/EBP factors are highly expressed in these cells and it was shown that several Myb-inducible genes, such as mim-1, tom-1 and the lysozyme and C/ EBPb genes are activated synergistically by v-Myb and C/EBP family members. We were therefore interested to investigate whether the promoter of the A2B-AR gene is also activated synergistically by v-Myb and C/ EBP. As shown in Figure 6 , this was not the case. Although C/EBPa, b and d activated the A2B-AR promoter on their own, none of them acted synergistically with v-Myb. In these experiments we have used the E26 version of v-Myb and the same v-Myb construct synergizes with C/EBP factors on the mim-1 and tom-1 promoter (Burk et al., 1993 . This indicates that the regulation of the promoter of the We also investigated whether v-Myb cooperates with other transcription factors previously implicated as partners for Myb in myelomonocytic cells, such as Ets-1, Ets-2 and AML1, however, none of these proteins had a significant effect on the activity of the A2B-AR promoter, either in the presence or the absence of vMyb (data not shown).
Analysis of A2B-AR promoter in erythroid cells
The A2B adenosine receptor gene is unique among the known Myb inducible genes in that it is expressed in myelomonocytic as well as in erythroid cells while other hematopoietic cells, such as B-or T-lymphoid cells do not express the gene . We were therefore interested to know whether Myb was also required for the activity of the A2B-AR promoter in erythroid cells. We first determined whether the same promoter is used in erythroid and myelomonocytic cells. To this end we perfomed a nuclease S1 mapping experiment following the strategy outlined in Figure 7a and using mRNA from myelomonocytic (BM2), erythroid (HD3) and lymphoid (SC2L) cell lines. As pointed out before, the BM2 cell line expresses v-Myb while the erythroid and lymphoid cell lines express cMyb. The erythroid and myelomonocytic cells yielded similar patterns of S1-resistant DNA fragments indicating that transcription of the A2B-AR gene starts at the same sites in these cells. The intensity of the bands was slightly weaker in case of the erythroid cells, consistent with the fact that these cells express somewhat lower levels of A2B-AR mRNA than the myelomonocytic cells used (Worpenberg et al., 1997a) . By contrast, no S1-resistant fragments were observed in case of the lymphoid cells which express no A2B-AR mRNA and were used as negative control. We concluded from this experiment that the same promoter is used to transcribe the A2B-AR gene in myelomonocytic and erythroid cells.
To study whether the Myb binding sites are also functional in erythroid cells we transfected some of the point-mutated reporter genes into the erythroblasts and determined their activities (Figure 7b ). Similar to v-myb transformed myeloblasts most single site mutations decreased the activity of the promoter slightly whereas mutation of all of the Myb binding sites had a strong inhibitory effect, suggesting that the Myb binding sites are essential for promoter activity also in erythroid cells.
We noted that a potential GATA-1 binding site, TGATA, is situated between Myb binding sites B and Figure 1 ). Since this sequence fits perfectly to the GATA-1 consensus binding site and because Myb and GATA-1 have been reported to cooperate during the activation of the Wilms tumor gene 1 (Zhang et al., 1997) we considered the possibility that Myb and GATA-1 might also act synergistically at the A2B-AR promoter. To address this possibility we generated two mutants of the promoter in which the GATA-1 site was changed from TGATAA to TCCTAA or TATTAA. The mutants were designed in such a way that the Myb binding sites were not affected. The resulting reporter genes were as inducible by cotransfecting Myb as the wild-type construct, confirming that the mutations had not affected the Myb binding sites (data not shown). Importantly, both mutants had the same activity in erythroid cells as the wild-type promoter (Figure 7b ) suggesting that factors binding to this particular GATA-1 binding site do not contribute to A2B-AR promoter activity in erythroid cells.
Discussion
Numerous studies have suggested that v-myb interferes with the differentiation program of myelomonocytic cells by deregulating the expression of specific target genes, thereby causing transformation of these cells. A number of genes have been identified as bona fide vmyb targets, including mim-1, tom-1, bcl-2, GBX2, Pdcd4 and the genes encoding A2B-AR, C/EBPb and lysozyme (Ness et al., 1989; Frampton et al., 1996; Taylor et al., 1996; Burk et al., 1997; Introna et al., Worpenberg et al., 1997; Kowenz-Leutz et al., 1997; Mink et al., 1999; Schlichter et al., 2001a) . While the roles of these genes in v-myb induced transformation or in normal hematopoiesis are not yet fully understood, their promoters have been used as tools to dissect the molecular mechanisms by which Myb regulates the expression of its targets. As a result it is now well established that the members of the C/EBP family play key roles in Myb-dependent gene activation in the myelomonocytic lineage of the hematopoietic system. Several of the Myb target genes, including mim-1, tom-1, the lysozyme gene and the C/EBPb gene, are activated in a combinatorial fashion by v-Myb or cMyb together with members of the C/EBP family (Burk et al., 1993 Ness et al., 1993; Mink et al., 1999) . In the hematopoietic system C/EBP factors are expressed at high levels mainly in the myelomonocytic lineage, suggesting that their role as cooperation The columns show the average activity of the luciferase reporter genes. Cells were analysed as described above. The activity of the wild-type promoter construct (pGL3-i11/5WT) was designated as 100%. Thin lines show standard deviations partners for Myb is restricted to these cells (Natsuka et al., 1992; Scott et al., 1992; Katz et al., 1993; Lekstrom-Himes and Xanthopoulos, 1998) . Consistent with this notion those Myb target genes which are activated cooperatively by Myb and C/EBP are expressed only in myelomonocytic cells. The relevance of the combinatorial action of Myb and C/EBP is further substantiated by the finding that ectopic expression of Myb and C/EBP family members in non-hematopoietic cells can reprogram these cells to express myelomonocytic-specific genes, such as mim-1 or the lysozyme gene (Burk et al., 1993; Ness et al., 1993) . In contrast to myelomonocytic cells much less is known about the molecular mechanisms of gene activation by Myb and its cooperation partners in other hematopoietic lineages. Several genes have been identified as Myb targets in T-lymphoid cells, such as the CD4, RAG2 and the TCRg and d genes (Siu et al., 1992; Hernandez-Munain and Krangel, 1995; Wang et al., 2000; Reizis and Leder, 2001) . In each case a single Myb binding site was found to be crucial for Mybinducibility, suggesting that Myb also requires cooperating factors in T-lymphoid cells. However, a cooperating partner for Myb so far has only been identified in case of the TCRd gene (HernandezMunain and Krangel, 1995).
The chicken A2B-AR gene was originally cloned as a v-myb inducible gene in myelomonocytic cells . The gene is also expressed in erythroid cells where it is under the control of cMyb, as we have demonstrated here. Thus, the A2B-AR gene is of particular interest as a Myb target because it offers the opportunity to study the mechanisms by which Myb activates genes in multiple hematopoietic lineages. The data presented here suggest that the regulation of the A2B-AR gene by Myb differs significantly from the regulation of most other Myb target genes. The feature of the A2B-AR promoter that distinguishes it from most other Mybresponsive promoters analysed so far is the presence of an exceptionally large number of Myb binding sites many of which contribute to the Myb-inducibility of the promoter. The presence and functionality of these binding sites suggests that the activity of the promoter is dependent on the binding of a large number of Myb molecules rather than on the cooperation of a single (or a few) Myb molecules with specific cooperation partners, as in the case of many other Myb-regulated genes. In support of this idea we have been unable to demonstrate synergy of Myb with several other transcription factors that have been identified as cooperation partners for Myb before. A situation somewhat similar to the one described here for the A2B-AR promoter has been found in case of the chicken Pdcd4 gene, whose promoter was identified recently (Schlichter et al., 2001b) . The Pdcd4 promoter also contains a large number of Myb binding sites and, like the A2B-AR promoter, was also not activated synergistically by Myb and other known cooperation partners (Schlichter et al., 2001b) . Interestingly, the expression of the Pdcd4 gene, like that of the A2B-AR gene, is not restricted to myelomonocytic cells but is detected in cells belonging to multiple hematopoietic lineages. It therefore appears that the A2B-AR and Pdcd4 promoters exemplify a distinct type of Mybinducible promoter whose activation by Myb depends on the simultaneous binding of a large number of Myb molecules. This mode of activation may provide a simple mechanism for activating the expression of a target gene by Myb independently of other lineagespecific transcription factors. It is clear, however, that not all cells which express Myb also express the A2B-AR gene. Possibly, other regulatory regions of the gene, such as cell-specific enhancers or silencers, restrict its expression to particular cell types. Alternatively, the A2B-AR gene might be inaccessible to Myb in certain cell types due to a condensed chromatin structure. Clearly, further work is needed to fully understand the mechanisms controlling the cell type specific expression of the A2B-AR gene.
Materials and methods
Cells
QT6, a line of chemically transformed japanese quail fibroblasts (Moscovici et al., 1977) , was grown in Iscoves' modified DMEM supplemented with 8% fetal calf serum and 2% chicken serum. BM2 is a line of AMV-transformed myeloblasts grown in RPMI 1640 medium supplemented with 10% tryptose phosphate broth, 8% fetal calf serum and 2% chicken serum. HD3 is a line of AEV-transformed chicken erythroblasts grown in RPMI 1640 medium supplemented with 8% fetal calf serum and 2% chicken serum. SC2L is a chicken B-cell line (Chen et al., 1983) and was grown in RPMI 1640 medium supplemented with 8% fetal calf serum, 2% chicken serum and 32 mM b-mercaptoethanol.
Isolation of genomic A2B receptor clones
A lEMBL-3 Sp6/T7 genomic library of chicken liver DNA (Clontech) was screened under high stringency conditions with an approximately 0.6 kb PstI/BglII probe fragment derived from the 5' end of a chicken A2B receptor cDNA clone . Insert fragments of positive phages were subcloned into pBluescript vector. Nucleotide sequencing was performed by the chain-terminator technique.
Nuclease S1 mapping Nuclease S1 mapping was performed according to previously published procedures . The radiolabeled probe fragment spanning the 5' region of the A2B receptor gene was prepared by first end-labeling a synthetic oligonucleotide corresponding to nucleotides +238 to +258 of the sequence shown in Figure 1 with T4-Polynucleotide-Kinase and 32 P-g-ATP. The oligonucleotide was then used as a primer to synthesize an end-labeled probe. For this purpose the oligonucleotide was hybridized to a genomic A2B receptor clone, extended using Klenow polymerase and digested with BamHI. The BamHI site is located at position 7518 to 7523 of the sequence shown in Figure 1 . Finally, the radiolabeled probe fragment, which spans nucleotides 7522 to +258 of the sequence shown in Figure 1 , was purified by alkaline agarose gel electrophoresis. Hybridization of the probe to mRNA, nuclease S1 digestion and analysis of the S1-resistant DNA were performed as described before To determine the exact size of the S1-resistant fragments the radiolabeled oligonucleotide was used as a primer in standard chain termination sequencing reactions and aliquots of the sequencing reactions were used as markers.
Reporter genes and transfections
The luciferase reporter gene pi11/5(71945)Luc was obtained by inserting a NotI/SmaI-fragment (containing promoter sequences from 71945 to +218 bp) from the genomic A2B-AR clone into pGL3 basic (Promega). Promoter constructs with 5' deletions were generated by using appropriate restriction sites. The b-galactosidase reporter gene pCMVb was obtained from Clontech. Expression vectors for v-Myb (pVM134, pcDE26v-myb), a frameshift-version of v-Myb (pVM111) and a N-terminal deletion mutant of v-Myb lacking the DNA-binding domain (pVM130) have been described before Burk and Klempnauer, 1999) . Expression vectors for chicken C/EBPa and b and mouse C/EBPd have been described (Mink et al., 1999; Cao et al., 1991) . DNA transfection using QT6 cells was performed as described (Burk et al., 1993) . For electroporation, cells were suspended in phosphate-buffered saline at a concentration of 6610 6 cells per 300 ml. Electroporation was carried out at 300 V and 900 mF. Cells were then transferred to fresh growth medium and harvested after 24 h. The preparation of cell extracts, luciferase and b-galactosidase assays was performed as described (Burk et al., 1993) .
Mutagenesis
Mutagenesis was carried out using the QuikChangeTM SiteDirected mutagenesis system (Promega). The parental construct (pGL3-i11/5WT) for all mutants was similar to pi11/5(7231)Luc except that a stretch of GC-rich sequences between +109 and +218 bp was deleted. Constructs with multiple mutations were generated by successive rounds of mutagenesis. 
Gel retardation assays
The following pairs of single-stranded oligonucleotides were annealed and used for gel retardation assays: WTA: 5'AG-CTCATCGCGCCGTTCGCGGGGATTTTTCTCTG3' and 5' CAGAGAAAAAT CCCCGCGAACGGCGCGAT GAG3 ' MutA: 5'AGCTCATCGCGCCTCACGCGGGGATTTTTC-TCTG3' and 5'CACAGAGAAAAATCCCCGCGTGAGG-CGCGATGAG3' WTB: 5'TCAGGGGCGCCCCTCGGTG-TGATAACGGTCCGCAG3' and 5'CGTCTGCGGACCGT-TATCACACCGAGGGGCGCCCCTGA3' WTC: 5'TCAG-GGGCGCCCCGTTGTGTGATAGTGGTCCGCAG3' and 5'CGTCTGCGGACCACTATCACACAACGGGGCGCCC-CTGA3' WTD: 5'TCAGGAACGTTCCTCGGTGTGATA-GTGGTCCGCAG3' and 5'CGTCTGCGGACCACTATCA-CACCGAGGAACGTTCCTGA3' WTBCD: 5'GCCACTT-CTTACATCAGGAACGT TCCGT TGTGTGATAACGGT-CCGCAGACGAAGTG3' and 'GCACTTCGTCTGCGGA-CCGTTATCACACAACGGAACGT TCCTGATGTAAGA-AGTGG3' MutBCD: 5'GCCACTTCTTACATCAGGGGC-GC C C CTCGGTGTGATAGTGGTC CGCAGACGAAGT-G3' and 5'GCACTTCGTCTGCGGACCACTATCACACC-GAGGGGCCGCCCCTGATGTAAGAAGTGG3' WTE: 5'GCTTTGGTAACCGTTATGGTTTGC3' and 5'GGCAA-ACCATAACGGTTACCAAAG3' MutE: 5'GCTTTGGTA-ACCTCCATGGTTTGC3' and 5'GGCAAACCATGGAGG-TTACCAAAG3'.
After annealing, oligonucleotides were radiolabeled by filling-in of the ends using a 32 P-dCTP. Bacterial v-Myb protein was prepared and binding experiments were performed as described (Oehler et al., 1990) .
